Search Results
Jul 23, 2026, 08:00 ET Plume Names Peter Wulfraat Chief Revenue Officer to Accelerate Global ISP Growth
"Peter brings a rare combination of an ability to articulate complex platform value to global C-suite decision makers, the operational discipline to lead high-performance
More news about: Plume Design, Inc.
Jul 23, 2026, 07:31 ET Le pôle pétrochimique de la Méditerranée orientale, développé par Rönesans, attire plus de 3 milliards de dollars américains d'investissements
d'infrastructures industriellesau sein d' d'un écosystème unique intégré – et de plus en plus rare et attractif . »Surbana Jurong Partenariat Lieux DAPEK sur le Radar de International Investisseurs«
More news about: Rönesans Holding
Jul 23, 2026, 07:05 ET Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD). For more information about Viking Therapeutics, please visit
More news about: Viking Therapeutics, Inc.
Jul 23, 2026, 07:00 ET Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining,
More news about: Insmed Incorporated
Jul 23, 2026, 07:00 ET Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
currently serves as Chairman and director of PTC Therapeutics, Inc. (Nasdaq: PTCT), a publicly traded biotechnology company focused on treatments for rare genetic disorders. He is also Chairman and a director of Berryville Holdings, which develops attribution and protection systems for the defense and
More news about: Hamilton Lane
Jul 23, 2026, 06:48 ET ART GARFUNKEL AND KATHRYN LUCE GARFUNKEL INVITE THE WORLD INTO THEIR EXTRAORDINARY LIFE AND LEGACY
Carrberry Companies."Art and Kathryn have created something truly rare. A partnership built on creativity, curiosity, and a genuine love of connecting with people. Through Your Home TV, audiences will experience not only
More news about: Your Home Digital LLC
Jul 23, 2026, 06:29 ET Lockheed Martin Reports Second Quarter 2026 Financial Results
programs, compliance with stringent performance and reliability standards, and materials availability, including government furnished equipment and rare earth minerals;performance and/or financial viability of key suppliers, teammates, joint ventures (including United Launch Alliance, for which
More news about: Lockheed Martin
Jul 23, 2026, 06:15 ET Energy Fuels Announces Conference Call and Webcast Details for Q2-2026 Earnings
July 23, 2026 /PRNewswire/ -- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium, rare earth elements, and critical materials, will hold a conference call on Thursday, August 6, 2026, at 9:00 AM Mountain Time to discuss its financial results
More news about: Energy Fuels Inc.
Jul 23, 2026, 06:00 ET Eastern Mediterranean Petrochemical Cluster Developed by Rönesans Attracts Over US$3 Billion in Investment
and industrial infrastructure within a single integrated ecosystem – an increasingly rare and attractive proposition."Surbana Jurong Partnership Places DAPEK on the Radar of International I
More news about: Rönesans Holding
Jul 23, 2026, 06:00 ET Eastern Mediterranean Petrochemical Cluster Developed by Rönesans Attracts Over US$3 Billion in Investment
and industrial infrastructure within a single integrated ecosystem – an increasingly rare and attractive proposition."Surbana Jurong Partnership Places DAPEK on the Radar of International I
More news about: Rönesans Holding
Jul 23, 2026, 05:55 ET RTX Reports Q2 2026 Results
exposures due to new tax legislation or other developments in the U.S. and other countries in which RTX and its businesses operate; (18) the identified rare condition in powder metal used to manufacture certain Pratt & Whitney engine parts requiring accelerated removals and inspections of a significant
More news about: RTX
Jul 23, 2026, 05:26 ET Sentante's CE-marked robotic platform is building the data foundation for endovascular physical AI
built on imaging alone is extracting more from a data source the field is deliberately driving down.Drive-side force and torque sensing remains rare in medical robotics; da Vinci 5 only brought force feedback to laparoscopy in March 2024, with preclinical evidence of up to
More news about: Sentante
Jul 23, 2026, 04:36 ET Forevermark Diamond Jewellery Enters East India
milestones. Rooted in rarity, authenticity and transparency, every piece is created using some of the world's most beautiful natural diamonds that are rare, responsibly sourced and brought to life through timeless design. The Kolkata boutique reflects the brand's vision of creating elevated retail experiences,
More news about: Forevermark Diamond Jewellery
Jul 23, 2026, 04:00 ET Efekta Education Appoints AI Veteran Matt Fisher as Chief Technology Officer
available, while ensuring technology strengthens and supports the critical role of teachers.Stephen Hodges, CEO of Efekta, added: "Matt brings a rare combination of deep technical expertise, product vision and leadership experience. He has spent nearly two decades building technologies at scale and
More news about: Efekta Education
Jul 23, 2026, 03:33 ET Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
potential of Lu AH69593. This program is a good example of Lundbeck's transformation of the R&D pipeline into breakthrough neurology, neuroendocrine and rare indication programs, with potential for regulatory designations facilitating development. We are encouraged by the opportunity to work closely with
More news about: H. Lundbeck A/S
Jul 23, 2026, 03:29 ET Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
potential of Lu AH69593. This program is a good example of Lundbeck's transformation of the R&D pipeline into breakthrough neurology, neuroendocrine and rare indication programs, with potential for regulatory designations facilitating development. We are encouraged by the opportunity to work closely with
More news about: H. Lundbeck A/S
Jul 23, 2026, 03:00 ET Kavalan Named 'Whisky of the Year' For Second Year Running at IWC 2026
world's most respected whisky competitions, inspiring us to keep exploring new possibilities for Taiwanese single malt.""Kavalan has accomplished a rare feat by winning Whisky of the Year two years in a row at one of the industry's most demanding blind tasting competitions," said Max A. Solano, Director
More news about: Kavalan Whisky
Jul 23, 2026, 03:00 ET Kavalan élu Whisky de l'année pour la deuxième année consécutive lors de l'IWC 2026
au monde, ce qui nous incite à continuer d'explorer de nouvelles possibilités pour le single malt taïwanais. »« Kavalan a réalisé un exploit rare en remportant le titre de Whisky de l'année deux années de suite lors de l'un des concours de dégustation à l'aveugle les plus exigeants du secteur »,
More news about: Kavalan Whisky
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
tissue delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional
More news about: ARTHEx Biotech
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
tissue delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional
More news about: ARTHEx Biotech
Jul 23, 2026, 02:08 ET Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
Tablets offers patients with PNH a new, safe and convenient treatment option.Focusing on Rare Diseases and Addressing Unmet Clinical NeedsParoxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired clonal disorder of hematopoietic stem cells. The disease is primarily characterized by
More news about: Haisco Pharmaceutical Group Co., Ltd.
Jul 22, 2026, 18:29 ET Quantinuum nomme sa directrice juridique et son directeur des ressources humaines
culture d'entreprise et l'infrastructure qui accompagneront Quantinuum dans sa nouvelle étape en tant que société cotée en bourse. C'est une occasion rare de contribuer à façonner une organisation à la pointe d'une technologie qui marquera les décennies à venir. »À propos de QuantinuumQuantinuum
More news about: Quantinuum
Jul 22, 2026, 16:15 ET Quantinuum Appoints Chief Legal Officer and Chief People Officer
of rapid growth, I'm excited to build the people, culture, and infrastructure that will support Quantinuum's next chapter as a public company. It's a rare opportunity to help shape an organization at the forefront of a technology that will define the coming decades."About QuantinuumQuantinuum
More news about: Quantinuum
Jul 22, 2026, 16:15 ET Quantinuum Appoints Chief Legal Officer and Chief People Officer
of rapid growth, I'm excited to build the people, culture, and infrastructure that will support Quantinuum's next chapter as a public company. It's a rare opportunity to help shape an organization at the forefront of a technology that will define the coming decades."About QuantinuumQuantinuum
More news about: Quantinuum
Jul 22, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD). For more information about Viking Therapeutics, please visit
More news about: Viking Therapeutics, Inc.